Differences in Clinical Responses to Ustekinumab Treatment among Body Regions: Results from a Real-World Prospective, Observational, and Multi-Center Study in Korea
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: In psoriasis treatment, not all body regions improve simultaneously after clinical interventions. Objective: This study was aimed at evaluating clinical responses across body regions, which may differentially influence patient treatment plans. Methods: This prospective, observational, and multi-center study was conducted in Ko- reans who adhered to ustekinumab treatment based on criteria per local label and reim- bursement guidelines. A total of 581 were included in this analysis. Results: The mean (±standard deviation) psoriasis area severity index (PASI) score at baseline, age, disease duration, and body surface area (%) were 18.9±9.69, 44.2±13.29 years, 11.3±9.65 years, and 27.8±17.83, respectively. Across the head and neck, upper extremities, trunk, and lower extremities, the correlation between the PASI sub-scores for the upper and lower extremities was the highest (r=0.680). The mean PASI sub-score for the lower extremities was the highest at baseline. PASI90 and PASI100 scores were the highest for the head and neck region, indicating the highest response rates, while those for the lower extremities were consistently low at all visits. Conclusion: We found differences in regional ustekinumab responses, with the lower ex- tremities being the most difficult to treat. These findings should be considered in psoriasis treatment.
Abstract
Background: In psoriasis treatment, not all body regions improve simultaneously after clinical interventions. Objective: This study was aimed at evaluating clinical responses across body regions, which may differentially influence patient treatment plans. Methods: This prospective, observational, and multi-center study was conducted in Ko- reans who adhered to ustekinumab treatment based on criteria per local label and reim- bursement guidelines. A total of 581 were included in this analysis. Results: The mean (±standard deviation) psoriasis area severity index (PASI) score at baseline, age, disease duration, and body surface area (%) were 18.9±9.69, 44.2±13.29 years, 11.3±9.65 years, and 27.8±17.83, respectively. Across the head and neck, upper extremities, trunk, and lower extremities, the correlation between the PASI sub-scores for the upper and lower extremities was the highest (r=0.680). The mean PASI sub-score for the lower extremities was the highest at baseline. PASI90 and PASI100 scores were the highest for the head and neck region, indicating the highest response rates, while those for the lower extremities were consistently low at all visits. Conclusion: We found differences in regional ustekinumab responses, with the lower ex- tremities being the most difficult to treat. These findings should be considered in psoriasis treatment.
참고문헌 (16)
- 송해준, "The Clinical Profile of Patients with Psoriasis in Korea: A Nationwide Cross-Sectional Study (EPI-PSODE)", Annals of Dermatology, 29(4), pp.462~470 (2017), 대한피부과학회
- Leonardi CL, "Efficacy and safety of ustekinumab, a human interleukin-12", 23 monoclonal antibody, in patients with psoriasis : 76-week results from a randomised, double-blind, placebo-controlled trial(PHOENIX 1), 2008, pp.371, 1665~1674
- Papp KA, "Efficacy and safety of ustekinumab, a human interleukin-12", 23 monoclonal antibody, in patients with psoriasis : 52-week results from a randomised, double-blind, placebo-controlled trial(PHOENIX 2), 2008, pp.371, 1675~1684
- Sawyer LM, "Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis : a systematic review and network meta-analysis of PASI response", J Eur Acad Dermatol Venereol, 33, pp.355~366 (2019)
- Fredriksson T, "Severe psoriasis : oral therapy with a new retinoid", Dermatologica, 157, pp.238~244 (1978)
- Youn SW, "Clinical outcomes in adult patients with plaque psoriasis treated with ustekinumab under real-world practice in Korea : a prospective, observational, multi-center, postmarketing surveillance study", J Dermatol, 48, pp.778~785 (2021)
- Young Park J, "Facial psoriasis : comparison of patients with and without facial involvement", J Am Acad Dermatol, 50, pp.582~584 (2004)
- Sampogna F, "Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex", Acta Derm Venereol, 94, pp.411~414 (2014)
- Zampieron A, "Quality of life in patients with scalp psoriasis", G Ital Dermatol Venereol, 150, pp.309~316 (2015)
- Griffiths CE, "Pathogenesis and clinical features of psoriasis", Lancet, 370, pp.263~271 (2007)
- Larko O, "Problem sites : scalp, palm and sole, and nail", Dermatol Clin, 13, pp.771~777 (1995)
- Wozel G, "Psoriasis treatment in difficult locations : scalp, nails, and intertriginous areas", Clin Dermatol, 26, pp.448~459 (2008)
- Kimball AB, "The psychosocial burden of psoriasis", Am J Clin Dermatol, 6, pp.383~392 (2005)
- Youn SW, "The relationship between clinical characteristics including presence of exposed lesions and health-related quality of life(HRQoL)in patients with psoriasis : analysis from the nationwide epidemiologic study for psoriasis in Korea(EPI-PSODE study)", J Eur Acad Dermatol Venereol, 32, pp.1499~1506 (2018)
- Hjuler KF, "Localization of treatment-resistant areas in patients with psoriasis on biologics", Br J Dermatol, 181, pp.332~337 (2019)
- Sánchez-Regaña M, "Evidence-based guidelines of the spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites(nails, scalp, palms, and soles)", Actas Dermosifiliogr, 105, pp.923~934 (2014)